After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they will be prohibiting like-for-like compounded versions.

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available after a decision by the U.S. Food and Drug Administration. The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply.